Voglibose | CAS#83480-29-9 | alpha-Glucosidase Inhibitor

MedKoo Cat#: 318983 | Name: Voglibose

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus. Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal. There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest. Voglibose has fewer side effects than both acarbose and miglitol. But acarbose has an edge over voglibose in terms of efficacy (FPG, PPHG, HBA1c).

Chemical Structure

Voglibose

CAS#83480-29-9

Theoretical Analysis

MedKoo Cat#: 318983

Name: Voglibose

CAS#: 83480-29-9

Chemical Formula: C10H21NO7

Exact Mass: 267.1318

Molecular Weight: 267.28

Elemental Analysis: C, 44.94; H, 7.92; N, 5.24; O, 41.90

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 350.00
50mg	USD 500.00
100mg	USD 750.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

AO-128, AO 128, AO128, Glustat, Vocarb, Basen, Basen OD, Voglibose, Voglib

IUPAC/Chemical Name

(1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol

InChi Key

FZNCGRZWXLXZSZ-CIQUZCHMSA-N

InChi Code

InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

SMILES Code

O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](NC(CO)CO)C1

Appearance

White to off-white crystalline powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 267.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Wang A, Xu M, Li L, Li J. Atypical diabetes arising from SHORT syndrome: a case report. Front Endocrinol (Lausanne). 2024 Dec 13;15:1467364. doi: 10.3389/fendo.2024.1467364. PMID: 39735640; PMCID: PMC11671247. 2: Ghorbani H, Minasyan A, Ansari D, Ghorbani P, Wood DA, Yeremyan R, Ghorbani S, Minasian N. Anti-diabetic therapies on dental implant success in diabetes mellitus: a comprehensive review. Front Pharmacol. 2024 Dec 11;15:1506437. doi: 10.3389/fphar.2024.1506437. PMID: 39723258; PMCID: PMC11668599. 3: Ayan EK, Çoban G, Soyer Z. Design, synthesis, biological evaluation, and molecular modeling studies of some quinazolin-4(3H)-one- benzenesulfonamide hybrids as potential α-glucosidase inhibitors. J Biomol Struct Dyn. 2024 Nov 14:1-21. doi: 10.1080/07391102.2024.2427373. Epub ahead of print. PMID: 39539169. 4: Seraj F, Naz F, Özil M, Baltaş N, Tariq SS, Ul-Haq Z, Salar U, Taha M, Khan KM. Synthesis of arylated tetrahydrobenzo[H]quinoline-3-carbonitrile derivatives as potential hits for treatment of diabetes. Future Med Chem. 2024 Dec;16(24):2609-2625. doi: 10.1080/17568919.2024.2419359. Epub 2024 Nov 12. PMID: 39530526. 5: Rocha P, Rebelo P, Pacheco JG, Geraldo D, Bento F, Leão-Martins JM, Delerue- Matos C, Nouws HPA. Electrochemical molecularly imprinted polymer sensor for simple and fast analysis of tetrodotoxin in seafood. Talanta. 2025 Jan 1;282:127002. doi: 10.1016/j.talanta.2024.127002. Epub 2024 Oct 9. PMID: 39383719. 6: Arshad U, Shafiq N, Parveen S, Rashid M. Discovery of novel dihydro- pyrimidine hybrids: insight into the design, synthesis, biological evaluation and absorption, distribution, metabolism and excretion studies. Future Med Chem. 2024;16(19):1949-1969. doi: 10.1080/17568919.2024.2389767. Epub 2024 Sep 12. PMID: 39263831; PMCID: PMC11485738. 7: Son H, Lee BH, Cho YM. Theragnostic utility of continuous glucose monitoring in post-gastrectomy hypoglycemia. J Diabetes Investig. 2024 Nov;15(11):1696-1699. doi: 10.1111/jdi.14299. Epub 2024 Aug 28. PMID: 39196672; PMCID: PMC11527813. 8: Khan F, Khan MV, Kumar A, Akhtar S. Recent Advances in the Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies. Curr Drug Targets. 2024 Aug 8. doi: 10.2174/0113894501313365240722100902. Epub ahead of print. PMID: 39129156. 9: Sarkar A, Chakrabarti A, Bhaumik S, Debnath B, Singh SS, Ghosh R, Zaki MEA, Al-Hussain SA, Debnath S. Parkia javanica Edible Pods Reveal Potential as an Anti-Diabetic Agent: UHPLC-QTOF-MS/MS-Based Chemical Profiling, In Silico, In Vitro, In Vivo, and Oxidative Stress Studies. Pharmaceuticals (Basel). 2024 Jul 21;17(7):968. doi: 10.3390/ph17070968. PMID: 39065816; PMCID: PMC11280426. 10: Khan F, Shah AA, Kumar A, Akhtar S. In Silico Investigation against Inhibitors of Alpha-Amylase Using Structure-based Screening, Molecular Docking, and Molecular Simulations Studies. Cell Biochem Biophys. 2024 Sep;82(3):2873-2888. doi: 10.1007/s12013-024-01403-9. Epub 2024 Jul 9. Erratum in: Cell Biochem Biophys. 2024 Aug 28. doi: 10.1007/s12013-024-01490-8. PMID: 38982021. 11: Lv Q, Yang Y, Lv Y, Wu Q, Hou X, Li L, Ye X, Yang C, Wang S. Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis. Front Endocrinol (Lausanne). 2024 May 31;15:1403606. doi: 10.3389/fendo.2024.1403606. PMID: 38883606; PMCID: PMC11176463. 12: Kawai F, Watanabe S, Ebihara H, Shimizu N, Oshima S, Okai H, Murata Y, Arai H, Matsuo K. Recurrent reactive hypoglycemia due to clozapine-induced glucose intolerance: A case report. PCN Rep. 2023 Dec 21;2(4):e162. doi: 10.1002/pcn5.162. PMID: 38868726; PMCID: PMC11114382. 13: Parmar N, Gupta AK, Jhaveri K, A B, Chhaya G, Kansara S, Nair R, Korukonda KR. Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus. Cureus. 2024 Apr 3;16(4):e57494. doi: 10.7759/cureus.57494. PMID: 38707131; PMCID: PMC11066517. 14: Shamanna P, Jha PK, Makwana A, Shukla H, Bavishi C. Observational, Multicenter, Retrospective, Study on the Usage Patterns of the Fixed Dose Combination of Glimepiride, Metformin, and Voglibose in Type 2 Diabetes Management. Cureus. 2024 Jan 10;16(1):e52064. doi: 10.7759/cureus.52064. PMID: 38348001; PMCID: PMC10859676. 15: Abchir O, Yamari I, Shtaiwi AM, Nour H, Kouali ME, Talbi M, Errougui A, Chtita S. Insights into the inhibitory potential of novel hydrazinyl thiazole- linked indenoquinoxaline against alpha-amylase: a comprehensive QSAR, pharmacokinetic, and molecular modeling study. J Biomol Struct Dyn. 2024 Feb 2:1-18. doi: 10.1080/07391102.2024.2310778. Epub ahead of print. PMID: 38305802. 16: Patel P, Shah D, Bambharoliya T, Patel V, Patel M, Patel D, Bhavsar V, Padhiyar S, Patel B, Mahavar A, Patel R, Patel A. A Review on the Development of Novel Heterocycles as α-Glucosidase Inhibitors for the Treatment of Type-2 Diabetes Mellitus. Med Chem. 2024;20(5):503-536. doi: 10.2174/0115734064264591231031065639. PMID: 38275074. 17: Ando T, Kondo M, Asada-Yamada Y, Kawai M, Asano-Hayami E, Hayami T, Motegi M, Ejima Y, Nagao E, Kasagi R, Nakai-Shimoda H, Asano S, Kato M, Yamada Y, Yura- Miura E, Ishikawa T, Sugiura-Roth Y, Kojima C, Naito E, Himeno T, Tsunekawa S, Kato Y, Nakamura J, Kamiya H. The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching. Diabetol Int. 2023 Sep 4;15(1):99-108. doi: 10.1007/s13340-023-00651-z. PMID: 38264217; PMCID: PMC10800311. 18: Tanaka K, Okada Y, Umezu S, Hashimoto R, Tomoyose Y, Tateyama R, Hori Y, Saito M, Tokutsu A, Sonoda S, Uemura F, Kurozumi A, Tanaka Y. Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial. J Diabetes Investig. 2024 Apr;15(4):449-458. doi: 10.1111/jdi.14138. Epub 2023 Dec 27. PMID: 38149694; PMCID: PMC10981143. 19: Hattori-Muroi K, Naganawa-Asaoka H, Kabumoto Y, Tsukamoto K, Fujisaki Y, Fujimura Y, Komiyama S, Kinashi Y, Kato M, Sato S, Takahashi D, Hase K. α-Glucosidase inhibitors boost gut immunity by inducing IgA responses in Peyer's patches. Front Immunol. 2023 Nov 1;14:1277637. doi: 10.3389/fimmu.2023.1277637. PMID: 38022673; PMCID: PMC10646501. 20: Chen Y, Xiao Y, Lian G, Yi J, Liu X. Pneumatosis intestinalis associated with α-glucosidase inhibitors: a pharmacovigilance study of the FDA adverse event reporting system from 2004 to 2022. Expert Opin Drug Saf. 2023 Nov 6:1-10. doi: 10.1080/14740338.2023.2278708. Epub ahead of print. PMID: 37929311.